5-year Prognostic Value of No-reflow Phenomenon After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction
Overview
Authors
Affiliations
Objectives: The objective of this study was to investigate the impact of no-reflow phenomenon on 5-year mortality among patients with acute ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI). This impact was also assessed in relation to infarct size.
Background: The impact of no-reflow on long-term mortality in patients with STEMI has been insufficiently studied.
Methods: This study included 1,406 patients with STEMI treated by primary PCI. No-reflow was diagnosed using angiographic criteria. Infarct size was measured with single-photon emission computed tomography imaging 7 to 14 days after the acute event. The primary outcome was 5-year mortality.
Results: The no-reflow phenomenon was diagnosed in 410 patients (29%). Infarct size was 15.0% (6.0% to 29.0%) of the left ventricle in the no-reflow group versus 8.0% (2.0% to 21.0%) of the left ventricle in the reflow group (p < 0.001). There were 132 deaths during follow-up. Of them, 59 deaths occurred among patients with no-reflow and 73 deaths occurred among patients with reflow (Kaplan-Meier estimates of 5-year mortality 18.2% and 9.5%, respectively; odds ratio: 2.02; 95% confidence interval: 1.44 to 2.82; p < 0.001). The Cox proportional hazards model adjusting for infarct size among other variables identified the no-reflow phenomenon as an independent correlate of 5-year mortality (hazard ratio: 1.66; 95% confidence interval: 1.17 to 2.36; p = 0.004).
Conclusions: In patients with STEMI treated by primary PCI, no-reflow phenomenon is a strong predictor of 5-year mortality. No-reflow phenomenon after PCI provides prognostic information that is independent of and beyond that provided by infarct size.
Li Z, Yin Y, Wei Y, Liu Y, Han N, Wang X J Mol Histol. 2025; 56(2):103.
PMID: 40063284 PMC: 11893718. DOI: 10.1007/s10735-025-10378-7.
Abramik J, Mariathas M, Felekos I J Clin Med. 2025; 14(4).
PMID: 40004660 PMC: 11856034. DOI: 10.3390/jcm14041128.
Assempoor R, Daneshvar M, Taghvaei A, Abroy A, Azimi A, Nelson J Cardiovasc Diabetol. 2025; 24(1):35.
PMID: 39844262 PMC: 11756160. DOI: 10.1186/s12933-025-02582-2.
Yang X, Yang J, Kashima Y, Hachinohe D, Sugie T, Xu S J Thorac Dis. 2024; 16(11):7771-7786.
PMID: 39678843 PMC: 11635223. DOI: 10.21037/jtd-24-1482.
SCAI Expert Consensus Statement on the Management of Patients With STEMI Referred for Primary PCI.
Tamis-Holland J, Abbott J, Al-Azizi K, Barman N, Bortnick A, Cohen M J Soc Cardiovasc Angiogr Interv. 2024; 3(11):102294.
PMID: 39649824 PMC: 11624394. DOI: 10.1016/j.jscai.2024.102294.